I‐Ting Teng

This paper evaluates co-administration of two intranasal parainfluenza virus vectors expressing distinct SARS-CoV-2 S antigens in hamsters, showing broad and durable immunity against Omicron/BA.5 challenge.

The paper shows that vaccine imprinting influences susceptibility to SARS-CoV-2 variants in children by linking immune history, antibody neutralization, and infection risk.

This paper improves an anti-malaria antibody to broaden its recognition of malaria parasite proteins and enhances its protective effectiveness against diverse strains.

This paper develops a nanoparticle-based junctional vaccine targeting PfCSP and compares its efficacy to the R21 vaccine in reducing malaria liver burden in mice.

This study designs a dual-epitope vaccine targeting HIV-1 Env's fusion peptide and V2 apex, showing it elicits neutralizing antibodies against both sites in rhesus macaques.

This study shows that transient glycan deletions in SHIVs can induce CD4-binding site broadly neutralizing antibodies in macaques, offering a model for HIV vaccine design.

This study evaluates intranasal B/HPIV3 vaccines expressing SARS-CoV-2 spike proteins of different variants, showing they induce mucosal and systemic immunity and protect hamsters against homologous and heterologous challenges.

This study identifies bat and mink ACE2 as receptors for HKU5 merbecovirus, revealing distinct receptor interactions and highlighting mustelids as potential intermediate hosts.

This study shows that mucosal adenoviral-vectored vaccines provide durable protection against XBB.1.16 infection in nonhuman primates, outperforming intramuscular boosting in reducing virus replication in both upper and lower airways.

The paper evaluates the effectiveness of an XBB.1.5 monovalent booster vaccine, showing improved antibody binding and neutralization against SARS-CoV-2 Omicron variants.